What is your approach to tapering therapy in a patient with recurrent pericarditis now well-controlled on rilonacept?

Good question, since rilonacept was only approved 1.5 years ago, a lot of this is gleaned (i.e. expert opinion) from those that participated in the Rhapsody clinical trial.

In terms of actual data, the long-term follow-up from Rhapsody was just presented at AHA.2022. Of those in the extension that de...

There is very little data to guide the weaning of Rilonacept.

When I started considering weaning treatment in some of my patients, I reached out to the company and to some colleagues. The company that produces Rilonacept basically suggested treatment for 2 years, in monotherapy, and then discontinua...